Sartorius, DE0006292006

Sartorius stock gains after Barclays lifts its target

Published on 09/08/2026 at 13:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius stock draws attention after Barclays raised its target to EUR 300 from EUR 260 on September 8, 2026. The shares traded at EUR 235.15 on Tradegate, while the company still carries its July 24, 2026 quarterly reset in the background.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern — Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius stock (DE0006292006) traded at EUR 235.15 on Tradegate at 09:10 on September 8, 2026, after Barclays raised its target to EUR 300 from EUR 260 and kept its Buy viewZonebourse. The stock was up 0.62 percent on the day and down 6.22 percent over five days, while year to date it was off 5.46 percent.

Barclays keeps the debate open

Zonebourse said James Gordon of Barclays sees the share as attractive and lifted the target by EUR 40, or 15.4 percent, to EUR 300 on September 8, 2026. That gives investors a fresh valuation marker against a close of EUR 233.70 and an average analyst target of EUR 271.21 from 20 analysts.

The move matters because the gap between the new Barclays target and the latest close is EUR 66.30, or 28.4 percent. It also leaves the stock below the consensus target by EUR 37.51, a 16.1 percent spread.

July results still set the tone

The latest company numbers in the search results remain the July 24, 2026 second-quarter update, where Sartorius reported a contrast between demand and tariff pressure, according to the same market coverage used by tradersZonebourse. The report date gives the current debate a clear anchor on revenue quality, margins and guidance.

For investors, the comparison is still the same: a stock priced at EUR 235.15 on September 8, 2026 sits close to the EUR 233.70 close and below the EUR 271.21 consensus target, while the July 24, 2026 report remains the last period explicitly tied to operating performance in the available results coverage.

Bioprocessing remains central

Sartorius is a supplier of pharmaceutical and laboratory equipment with two main divisions, bioprocess solutions and lab products. That mix matters because the business is still judged on how quickly bioprocess demand translates into margin recovery after the July 24, 2026 reset described in the results coverageZonebourse.

Stock stays near target range

Sartorius stock last changed hands at EUR 235.15 on September 8, 2026, with the latest close at EUR 233.70 and the average analyst target at EUR 271.21. The market is pricing the shares well below Barclays' new EUR 300 target, but still within sight of the broader analyst range.